XML 58 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
Notes Payable (Details Narrative) - USD ($)
3 Months Ended
Nov. 12, 2015
Jun. 26, 2015
Jan. 22, 2015
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Amount of loan obligation       $ 5,169,381   $ 7,471,148
Amortization of debt discount       $ 475,600  
Recognized amortization of deferred financing costs       44,041 66,039  
Unamortized debt issuance cost       119,508   163,549
Interest expense paid       (247,364) $ (431,264)  
June 26, 2015 Security Agreement [Member] | Quarter Ending September 30, 2015 [Member]            
Debt instrument interest rate percentage   2.00%        
Note payable   $ 250,000        
June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member]            
Note payable   700,000        
June 26, 2015 Security Agreement [Member] | Minimum [Member] | June 30, 2016 [Member]            
Note payable   $ 12,500        
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member]            
Debt instrument interest rate percentage     0.00%      
Note issued as part of asset purchase agreement     $ 1,500,000      
Note maturity date     Jan. 20, 2017      
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2016 [Member]            
Note payable     $ 750,000      
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2017 [Member]            
Note payable     750,000      
Security Agreement [Member] | June 26, 2015 Security Agreement [Member]            
Unamortized debt discount       1,307    
Payments of debt issuance costs       31,250    
Deferred financing costs       10,486    
Recognized amortization of deferred financing costs       1,293    
Interest expense paid       10,442    
Present value of future payments       288,889   $ 290,947
Knight Therapeutics Inc [Member] | Loan Agreement [Member]            
Loan amount $ 5,500,000   6,000,000      
Expences associated with loan $ 24,000   $ 40,000      
Debt instrument interest rate percentage 15.00%   15.00%      
Convertible equity offering     $ 1,000,000      
Change in loan interest rate 13.00%   13.00%      
Revenue     $ 13,000,000      
Net income (loss)     $ 2,000,000      
Amount of loan obligation       2,250,000    
Common stock purchase price per share $ 0.49          
Percentage of shares purchaseable under warrants 6.50%          
Deferred financing costs       289,045    
Recognized amortization of deferred financing costs       13,957    
Unamortized debt issuance cost       45,904    
Interest expense paid       103,740    
Accrued interest expense       0    
Note maturity date Nov. 11, 2017          
Warrants term 10 years          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | ST Warrant [Member]            
Number of warrants to purchase common stock     4,595,187      
Warrants exercise price     $ 1.00      
Beneficial conversion feature of warrants     $ 1,952,953      
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | LT Warrant [Member]            
Number of warrants to purchase common stock     3,584,759      
Warrants exercise price     $ 0.34      
Common stock purchase price per share     $ 1.00      
Percentage of shares purchaseable under warrants     25.00%      
Beneficial conversion feature of warrants     $ 1,462,560      
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrant Shares [Member]            
Number of warrants to purchase common stock 5,550,625          
Amortization of debt discount $ 2,553,287          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrant Shares One [Member]            
Number of warrants to purchase common stock 4,547,243          
Amortization of debt discount $ 2,067,258          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | January 22, 2015 Loan One [Member]            
Debt instrument interest rate percentage     5.00%      
Amount of loan obligation     $ 300,000      
Aggregate consideration to be paid     100,000      
Capital expenditures     100,000      
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrants [Member]            
Amount of loan obligation       2,750,000    
Deferred financing costs       233,847    
Recognized amortization of deferred financing costs       28,791    
Unamortized debt issuance cost       72,297    
Interest expense paid       128,906    
Recognized interest expense       120,430    
Accrued interest expense       $ 22,603    
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Origination Fee [Member]            
Expences associated with loan 110,000   120,000      
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Work Fee [Member]            
Expences associated with loan $ 55,000   $ 60,000      
Neuragen Corp [Member] | June 26, 2015 Security Agreement [Member]            
Debt instrument interest rate percentage   0.00%        
Note issued as part of asset purchase agreement   $ 950,000        
Total payments of acquire assets   $ 1,200,000